Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Approval for Carbidopa and Levodopa Extended-Release Tablets USP, 25 mg/100 mg and 50 mg/200 mg.
The above information is a part of company’s filings submitted to BSE.